SonoClear receives US FDA breakthrough designation for its SonoClear system for use in intracranial ultrasound procedures: Oslo, Norway Friday, July 4, 2025, 10:00 Hrs [IST] SonoC ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

KSPC launches maiden virtual simulation-based pharma manufacturing training programme: Our Bureau, Bengaluru Thursday, July 3 ...

Lifesciences industry adopts a wait-and-watch approach amid US tariff uncertainty: Aditya Sharma: Nandita Vijayasimha, Friday, July 4, 2025, 08:00 Hrs [IST] Lifesciences industry ...

The 10th edition of Pharmac South, the high-powered pharmaceutical and nutraceutical trade show, will open its doors today at the Chennai Trade Centre at Nandambakkam. The two-day event, running ...

Pharma industry eyes secure graphics & continuous data protection amid QR code counterfeit surge: Nandita Vijayasimha, Bengaluru Friday, July 4, 2025, 08:00 Hrs [IST] The pharmace ...

India and Myanmar in talks to fast-track approval for pharma products in Myanmar: Shardul Nautiyal, Mumbai Friday, July 4, 2025, 08:00 Hrs [IST] In a major development to boost ph ...

Govt to amend Rules to move preparations with higher alcoholic content to Schedule H1: Gireesh Babu, New Delhi Friday, July 4, 2025, 08:00 Hrs [IST] The Drugs Consultative Committ ...

Onward Medical submits two major regulatory applications for its ARC-EX system; seeking clearance to expand its indication for home use: Eindhoven, the Netherlands Thursday, July ...

Ensem Therapeutics doses first patient in phase 1/2 study of ETX-636, a novel allosteric pan-mutant-selective PI3Ka inhibitor and degrader: Waltham, Massachusetts Thursday, July 3 ...

CBI searches premises of PCI president Montu Kumar Patel, say reports: Our Bureau, New Delhi Thursday, July 3, 2025, 17:25 Hrs [IST] The Central Bureau of Investigation (CBI) has ...

Asahi Kasei Pharma begins phase III study of promising CIPN prevention therapy, Recomodulin to enhance treatment options worldwide: Chelmsford, Massachusetts Thursday, July 3, 202 ...